Has Gulshan Oberoi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,840 in general payments to Gulshan Oberoi, MD across 445 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gulshan Oberoi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gulshan Oberoi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gulshan Oberoi, MD

Neurology · Laurel, MSNPI 1174801765

Payments from drug & device makers

$7,840in general payments, 2019–2025

Across 445 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
SK Life Science, Inc.$1K
UCB, Inc.$701
Acadia Pharmaceuticals Inc$528
AstraZeneca$483
Lilly USA, LLC$312
plus $3K from 37 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	89	$1,314
SK Life Science, Inc.	49	$1,029
UCB, Inc.	45	$701
Acadia Pharmaceuticals Inc	29	$528
AstraZeneca(2 entities)	24	$483
Lilly USA, LLC	18	$312
Teva Pharmaceuticals USA, Inc.	16	$294
Pfizer	24	$288
Eisai Inc.	9	$270
Lundbeck LLC	13	$258
Sunovion Pharmaceuticals Inc.	17	$240
Argenx US, Inc.	10	$202
Sumitomo Pharma America, Inc.	10	$172
Novartis	7	$148
Adamas Pharmaceuticals, Inc.	5	$111
Upsher-smith Laboratories LLC	5	$110
Sanofi	7	$110
Genentech USA, Inc.	8	$104
Amgen	6	$101
Abbott	1	$96
Otsuka America Pharmaceutical, Inc.	4	$94
Supernus Pharmaceuticals, Inc.	6	$88
Biogen	4	$82
Biohaven Pharmaceuticals, Inc.	4	$70
GE HealthCare	4	$67
MDD US Operations, LLC	3	$65
Axsome Therapeutics, Inc.	3	$65
Johnson & Johnson	3	$62
ANI Pharmaceuticals, Inc.	2	$43
Avanir Pharmaceuticals, Inc.	3	$41
Sanofi-aventis U.S. LLC	2	$36
Corium, LLC	2	$35
Ceribell, Inc.	1	$31
Medtronic(2 entities)	2	$31
Catalyst Pharmaceuticals, Inc.	1	$31
Merz Pharmaceuticals, LLC	2	$30
Assertio Therapeutics, Inc.	1	$21
Mallinckrodt Hospital Products Inc.	1	$16
Avion Pharmaceuticals	1	$14
Biohaven Pharmaceutical Holding Company Ltd.	1	$12
Arbor Pharmaceuticals, Inc.	1	$12
Amneal Pharmaceuticals LLC	1	$11
Intercept Pharmaceuticals, Inc.	1	$11

How this compares

$7,840 in reported general payments places this provider in the 60th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$516,577

Medicare patients

967

Services billed

21,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Laurel

Aremmia TaniousLaurel$53K
Ronald SchwartzHattiesburg$5.6M
Stephen LandyTupelo$1.9M
Ruth FredericksJackson$943K
Wendell HelvestonJackson$883K
Paul BradleyMeridian$456K
Juebin HuangJackson$231K
Rajesh SharmaJackson$152K
Paula WarrenHattiesburg$114K
Justin GraffTupelo$85K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →